Terns Pharmaceuticals (NASDAQ:TERN) focuses on discovering, developing, and commercializing innovative therapies for significant unmet needs in the treatment of liver disease and cancer. With a deep commitment to addressing the challenges faced by patients with these life-threatening conditions, Terns operates with a vision to bring transformative treatments to the forefront. Their projects span across various stages of clinical development, leveraging both cutting-edge science and strategic partnerships to accelerate the development of their pipeline. The overarching objective of Terns is to improve patient outcomes through therapeutic advancements, embodying a patient-centric approach in everything from research to the eventual delivery of treatments. As it stands, Terns Pharmaceuticals is solely traded on the NASDAQ under the ticker symbol TERN, where it seeks to make a marked impact in the biopharmaceutical sphere by focusing on areas of high unmet medical need.